Evidence map›Paper›PMID 26556988›Full record

ReviewWorld journal of gastroenterology2015

Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?

Hiroshi Fukui

Abstract readReview
In one paragraph

Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Updates and Perspectives on Aquaporin-2 and Water Balance Disorders.International journal of molecular sciences · 2021
    Review
  2. Article
  3. Article
  4. Management of refractory cirrhotic ascites: challenges and solutions.Hepatic medicine : evidence and research · 2018
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Hyponatremia in the elderly: challenges and solutions.Clinical interventions in aging · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Hiroshi FukuiHiroshi Fukui, Department of Gastroenterology, Endocrinology and Metabolism, Nara Medical University, Kashihara, Nara 634-8522, Japan.
Nara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyponatremia is a frequent complication of advanced cirrhosis with ascites associated with increased morbidity and mortality. It is caused by an impairment in the renal capacity to eliminate solute-free water and is considered to be related to persistent secretion of vasopressin despite low serum osmolality. This nonosmotic release of vasopressin is mediated by the autonomic nervous system, which senses the underfilling of arterial vascular component. This reduction of effective arterial blood volume is closely related to the development of ascites. Although the short-time effects of vasopressin V2 receptor antagonists (vaptans) on hyponatremia and ascites have been repeatedly reported, their effects on the long-term management of cirrhotic ascites have not been established yet. Considering that their effects on water diuresis and their safety are limited by severe underfilling state of patients, cautious approaches with adequate monitoring are needed to advanced cirrhosis. Proper indication, adequate doses and new possibility of combination therapy should be explored in the future controlled study. As hyponatremia is frequent obstacle to ascites management, judicious combination with low-dose diuretics may decrease the incidence of refractory ascites. Although vaptans show much promise in the treatment of advanced cirrhosis, the problem of high cost should be solved for the future.

Indexed as

AnimalsAntidiuretic Hormone Receptor AntagonistsAquaporin 2AscitesBiomarkersHumansLiver CirrhosisNeurophysinsPatient SelectionProtein PrecursorsReceptors, VasopressinRisk FactorsTreatment OutcomeVasopressinsWater-Electrolyte BalanceAntidiuretic Hormone Receptor AntagonistsAQP2 protein, humanAquaporin 2AVP protein, humanAVPR2 protein, humanBiomarkersNeurophysinsProtein PrecursorsReceptors, VasopressinVasopressinsAscitesHyponatremiaLiver cirrhosisPathophysiologyV2 receptor antagonist

Identifiers

PMID26556988
PMCPMC4631962
OpenAlexW2395957688

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.